Article ID Journal Published Year Pages File Type
8528190 Clinical Therapeutics 2018 20 Pages PDF
Abstract
Fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin monotherapy. All groups treated with rosuvastatin and ezetimibe reported a decrease in mean LDL-C level >50%. The safety and tolerability of ezetimibe/rosuvastatin therapy were comparable with those of rosuvastatin monotherapy. ClinicalTrials.gov identifier: NCT02749994.
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Authors
, , , , , , , , , , , , , , , , , , , , , , , , , , ,